{"id":"concurrent-temozolomide","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Myelosuppression"},{"rate":"20-40%","effect":"Nausea and vomiting"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-15%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL810","moleculeType":"Small molecule","molecularWeight":"194.15"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Temozolomide is a prodrug that is converted into its active form, MTIC, which then methylates DNA, leading to DNA damage and cell death. This mechanism is particularly effective in cells that are rapidly dividing, such as cancer cells.","oneSentence":"Temozolomide is an alkylating agent that works by interfering with DNA replication in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:24.127Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glioblastoma multiforme"},{"name":"Anaplastic astrocytoma"}]},"trialDetails":[{"nctId":"NCT04574856","phase":"PHASE2","title":"Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-11-04","conditions":"Glioblastoma","enrollment":30},{"nctId":"NCT03197506","phase":"PHASE2","title":"Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-01-15","conditions":"Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma","enrollment":52},{"nctId":"NCT07485049","phase":"EARLY_PHASE1","title":"Phase 0/2 PD-Trigger Study of BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors","status":"NOT_YET_RECRUITING","sponsor":"Nader Sanai","startDate":"2026-04","conditions":"Glioblastoma (GBM)","enrollment":78},{"nctId":"NCT02287428","phase":"PHASE1","title":"Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-11","conditions":"Glioblastoma","enrollment":56},{"nctId":"NCT06504381","phase":"PHASE1, PHASE2","title":"DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-01-08","conditions":"High Grade Glioma, MGMT-Unmethylated Glioblastoma, MGMT-Methylated Glioblastoma","enrollment":70},{"nctId":"NCT07457307","phase":"PHASE1","title":"Integrating Biology for Safe Intensification of Glioblastoma Hypofractionated Treatment on the MR-Linac","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2026-06","conditions":"High-grade Glioma","enrollment":20},{"nctId":"NCT07452458","phase":"PHASE3","title":"Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"NRG Oncology","startDate":"2026-06-08","conditions":"Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma","enrollment":398},{"nctId":"NCT07195591","phase":"PHASE3","title":"Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care","status":"RECRUITING","sponsor":"GT Medical Technologies, Inc.","startDate":"2025-12-10","conditions":"Glioblastoma","enrollment":766},{"nctId":"NCT06622434","phase":"PHASE1, PHASE2","title":"New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-11-08","conditions":"Newly Diagnosed Glioblastoma","enrollment":35},{"nctId":"NCT04765514","phase":"PHASE2","title":"Chemoradiotherapy Versus Chemotherapy for Elderly and Frail GBM Patients","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2022-07-27","conditions":"Glioblastoma Multiforme","enrollment":107},{"nctId":"NCT03529448","phase":"PHASE1, PHASE2","title":"TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma","status":"COMPLETED","sponsor":"Grupo Español de Investigación en Neurooncología","startDate":"2023-08-18","conditions":"Glioblastoma","enrollment":33},{"nctId":"NCT05635734","phase":"PHASE1, PHASE2","title":"Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cantex Pharmaceuticals","startDate":"2023-09-05","conditions":"Glioblastoma","enrollment":18},{"nctId":"NCT03334305","phase":"PHASE1","title":"Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas","status":"TERMINATED","sponsor":"University of Florida","startDate":"2018-05-16","conditions":"Malignant Glioma, High Grade Glioma","enrollment":18},{"nctId":"NCT07365280","phase":"PHASE2","title":"Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"ZSky Biotech Inc","startDate":"2026-01-09","conditions":"Glioblastoma","enrollment":78},{"nctId":"NCT04752813","phase":"PHASE2","title":"A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)","status":"ACTIVE_NOT_RECRUITING","sponsor":"BPGbio","startDate":"2022-08-22","conditions":"Glioblastoma, Glioblastoma Multiforme","enrollment":50},{"nctId":"NCT00887146","phase":"PHASE3","title":"Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2009-09","conditions":"Brain and Central Nervous System Tumors","enrollment":305},{"nctId":"NCT06861244","phase":"PHASE2","title":"Embryonal Tumor With Multilayered Rosettes","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-03-06","conditions":"Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, Nos","enrollment":70},{"nctId":"NCT04677049","phase":"PHASE1, PHASE2","title":"Study of Niacin in Glioblastoma","status":"SUSPENDED","sponsor":"AHS Cancer Control Alberta","startDate":"2021-03-18","conditions":"Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype","enrollment":59},{"nctId":"NCT04165941","phase":"PHASE1","title":"Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2020-02-11","conditions":"Brain Tumor Adult","enrollment":22},{"nctId":"NCT04474353","phase":"PHASE1","title":"Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma","status":"COMPLETED","sponsor":"Stanford University","startDate":"2021-05-21","conditions":"Glioblastoma, Newly Diagnosed Glioblastoma","enrollment":12},{"nctId":"NCT03964090","phase":"PHASE2","title":"Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-27","conditions":"Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma","enrollment":48},{"nctId":"NCT03687957","phase":"PHASE1, PHASE2","title":"rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2019-01-04","conditions":"Glioma","enrollment":42},{"nctId":"NCT06831526","phase":"EARLY_PHASE1","title":"Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-11-06","conditions":"Glioblastoma","enrollment":12},{"nctId":"NCT04209790","phase":"PHASE2","title":"Neoadjuvant Chemoradiation for Resectable Glioblastoma","status":"TERMINATED","sponsor":"Geisinger Clinic","startDate":"2020-04-01","conditions":"Glioblastoma, Surgery, High Grade Glioma","enrollment":2},{"nctId":"NCT03396575","phase":"PHASE1","title":"Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)","status":"TERMINATED","sponsor":"University of Florida","startDate":"2018-07-17","conditions":"Diffuse Intrinsic Pontine Glioma (DIPG), Brain Stem Glioma","enrollment":11},{"nctId":"NCT04555577","phase":"PHASE1","title":"Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-09-20","conditions":"Glioblastoma, Gliosarcoma","enrollment":29},{"nctId":"NCT03174197","phase":"PHASE1, PHASE2","title":"Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-06-30","conditions":"Glioblastoma, Gliosarcoma","enrollment":60},{"nctId":"NCT00978458","phase":"PHASE3","title":"Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eastern Cooperative Oncology Group","startDate":"2009-11-17","conditions":"Brain and Central Nervous System Tumors, Neurotoxicity","enrollment":540},{"nctId":"NCT05190315","phase":"PHASE1","title":"Chlorpromazine and Standard of Care in Glioblastoma","status":"COMPLETED","sponsor":"Mohammed Milhem","startDate":"2022-01-28","conditions":"Glioblastoma Multiforme","enrollment":10},{"nctId":"NCT04747145","phase":"PHASE2","title":"Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2021-06-03","conditions":"Glioblastoma","enrollment":38},{"nctId":"NCT07020052","phase":"","title":"Phase II Exploratory Study of Sequential Triple Therapy (Temozolomide/Anlotinib/Bemarituzumab) in Combination With Concurrent Radiotherapy With Temozolomide and Anlotinib for the Maintenance Treatment of Diffuse Midline Gliomas in Children","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-07-10","conditions":"Maintenance Treatment of Diffuse Midline Gliomas in Children","enrollment":33},{"nctId":"NCT07047066","phase":"PHASE2","title":"A Phase II Clinical Study to Evaluate the Efficacy and Safety of Flazoparib Combined With Temozolomide After the Completion of Standard Concurrent Chemoradiotherapy (CCRT) in Newly Diagnosed Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-07-10","conditions":"Glioblastoma","enrollment":30},{"nctId":"NCT04477200","phase":"PHASE1","title":"Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-08-05","conditions":"Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Astrocytoma, Grade IV","enrollment":68},{"nctId":"NCT04730869","phase":"NA","title":"Metabolic Therapy Program In Conjunction With Standard Treatment For Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Waikato Hospital","startDate":"2021-05-26","conditions":"Glioblastoma","enrollment":18},{"nctId":"NCT06551909","phase":"NA","title":"Radioimmunotherapy in Solid Tumors (PNRR-MCNT2-2023-12378239-Aim2)","status":"RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2024-08-31","conditions":"Glioblastoma","enrollment":30},{"nctId":"NCT02655601","phase":"PHASE1, PHASE2","title":"Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001","status":"COMPLETED","sponsor":"BioMimetix JV, LLC","startDate":"2018-09-25","conditions":"High Grade Glioma, Astrocytoma, Grade III, Glioblastoma","enrollment":177},{"nctId":"NCT01777919","phase":"PHASE2","title":"Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform","status":"NOT_YET_RECRUITING","sponsor":"Olympion Medical Center","startDate":"2027-01","conditions":"Glioblastoma Multiforme","enrollment":32},{"nctId":"NCT05439278","phase":"PHASE3","title":"Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma","status":"RECRUITING","sponsor":"Severance Hospital","startDate":"2025-02-01","conditions":"Glioblastoma","enrollment":178},{"nctId":"NCT02715609","phase":"PHASE1, PHASE2","title":"Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2016-06-15","conditions":"Glioblastoma Multiforme","enrollment":35},{"nctId":"NCT04025541","phase":"NA","title":"Analysis of Circulating Tumor Markers in Blood","status":"RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2018-05-29","conditions":"Cancer, Breast Cancer, Sarcoma","enrollment":992},{"nctId":"NCT03344250","phase":"PHASE1","title":"Phase I EGFR BATs in Newly Diagnosed Glioblastoma","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2018-03-01","conditions":"Glioblastoma, Glioblastoma Multiforme","enrollment":16},{"nctId":"NCT04968366","phase":"PHASE1","title":"Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2021-07-30","conditions":"Glioblastoma Multiforme of Brain","enrollment":11},{"nctId":"NCT01849146","phase":"PHASE1","title":"Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-10-24","conditions":"Glioblastoma, Recurrent Glioblastoma","enrollment":74},{"nctId":"NCT04195139","phase":"PHASE2","title":"Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sydney","startDate":"2018-02-22","conditions":"Glioblastoma Multiforme","enrollment":103},{"nctId":"NCT05565521","phase":"PHASE2","title":"UNITy-BasED MR-Linac Adaptive Simultaneous Integrated Hypofractionated Boost Trial for High Grade Glioma in the Elderly","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2022-12-13","conditions":"Glioblastoma Multiforme, Adult, Glioblastoma, IDH-mutant","enrollment":55},{"nctId":"NCT05768919","phase":"PHASE1, PHASE2","title":"Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas","status":"RECRUITING","sponsor":"SignPath Pharma, Inc.","startDate":"2023-03-03","conditions":"Glioblastoma","enrollment":30},{"nctId":"NCT01985087","phase":"PHASE1, PHASE2","title":"A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Louisville","startDate":"2014-09","conditions":"Glioblastoma","enrollment":18},{"nctId":"NCT03363659","phase":"PHASE2","title":"Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2018-03-28","conditions":"Glioblastoma, Glioblastoma Multiforme","enrollment":15},{"nctId":"NCT05551013","phase":"","title":"Treatment of Recurrent GBM With APG-157 Via Expanded Access","status":"NO_LONGER_AVAILABLE","sponsor":"Aveta Biomics, Inc.","startDate":"","conditions":"Glioblastoma, Glioblastoma Multiforme","enrollment":""},{"nctId":"NCT06524063","phase":"PHASE1","title":"Targeted Survivin DC Cell Injection for the Treatment of GBM","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tricision Biotherapeutics Inc","startDate":"2024-08-01","conditions":"Glioblastoma","enrollment":9},{"nctId":"NCT00114140","phase":"PHASE2","title":"Temozolomide and Radiation Therapy in Treating Patients With Gliomas","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2005-01","conditions":"Brain and Central Nervous System Tumors","enrollment":136},{"nctId":"NCT06418113","phase":"PHASE1","title":"Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma","status":"RECRUITING","sponsor":"Hospital San Carlos, Madrid","startDate":"2024-03-21","conditions":"Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype","enrollment":12},{"nctId":"NCT03776071","phase":"PHASE3","title":"A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2020-12-16","conditions":"Glioblastoma","enrollment":260},{"nctId":"NCT02085304","phase":"PHASE1, PHASE2","title":"Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM","status":"TERMINATED","sponsor":"St. Joseph's Hospital and Medical Center, Phoenix","startDate":"2013-05-07","conditions":"Glioblastoma","enrollment":8},{"nctId":"NCT03927222","phase":"PHASE2","title":"Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma","status":"TERMINATED","sponsor":"Mustafa Khasraw, MBChB, MD, FRCP, FRACP","startDate":"2019-09-30","conditions":"Glioblastoma","enrollment":6},{"nctId":"NCT03466450","phase":"PHASE1, PHASE2","title":"Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma","status":"COMPLETED","sponsor":"Grupo Español de Investigación en Neurooncología","startDate":"2018-03-15","conditions":"Glioblastoma","enrollment":75},{"nctId":"NCT06330337","phase":"PHASE3","title":"Effect of Electroacupuncture Combined With Paclitaxel Clinical Efficacy of Patients With Recurrence of High-grade Glioma","status":"RECRUITING","sponsor":"The Third Affiliated hospital of Zhejiang Chinese Medical University","startDate":"2024-04-01","conditions":"Glioma","enrollment":58},{"nctId":"NCT03705351","phase":"PHASE1","title":"Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM","status":"TERMINATED","sponsor":"Providence Health & Services","startDate":"2019-12-02","conditions":"Glioblastoma, Cancer of Brain, Glioblastoma Multiforme","enrollment":7},{"nctId":"NCT02206230","phase":"PHASE2","title":"Trial of Hypofractionated Radiation Therapy for Glioblastoma","status":"COMPLETED","sponsor":"AHS Cancer Control Alberta","startDate":"2014-09-25","conditions":"Glioblastoma","enrollment":133},{"nctId":"NCT02432417","phase":"PHASE2","title":"The Addition of Chloroquine to Chemoradiation for Glioblastoma,","status":"WITHDRAWN","sponsor":"Maastricht Radiation Oncology","startDate":"2023-11-10","conditions":"Glioblastoma, Astrocytoma, Grade IV","enrollment":""},{"nctId":"NCT02530502","phase":"PHASE1","title":"Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2015-09-30","conditions":"Adult Glioblastoma","enrollment":4},{"nctId":"NCT03425292","phase":"PHASE1","title":"A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer","status":"COMPLETED","sponsor":"Saint John's Cancer Institute","startDate":"2018-03-01","conditions":"Newly Diagnosed High Grade Glioma","enrollment":49},{"nctId":"NCT06092255","phase":"NA","title":"A Study of SVZ Irradiation With Postoperative Radiotherapy in Patients With GBM.","status":"UNKNOWN","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2022-03-01","conditions":"GBM","enrollment":40},{"nctId":"NCT02659800","phase":"PHASE1","title":"Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-10-30","conditions":"Lymphopenia, Malignant Glioma","enrollment":12},{"nctId":"NCT04119674","phase":"PHASE1, PHASE2","title":"Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma","status":"COMPLETED","sponsor":"Zhejiang Cancer Hospital","startDate":"2019-03-19","conditions":"Glioblastoma","enrollment":33},{"nctId":"NCT00626990","phase":"PHASE3","title":"Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2007-12","conditions":"Brain and Central Nervous System Tumors","enrollment":751},{"nctId":"NCT00482677","phase":"PHASE3","title":"Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Canadian Cancer Trials Group","startDate":"2007-11-14","conditions":"Brain and Central Nervous System Tumors","enrollment":562},{"nctId":"NCT04532229","phase":"PHASE3","title":"Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children","status":"UNKNOWN","sponsor":"Biotech Pharmaceutical Co., Ltd.","startDate":"2021-04-03","conditions":"Diffuse Intrinsic Pontine Glioma","enrollment":48},{"nctId":"NCT04757662","phase":"PHASE1","title":"Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2021-05-14","conditions":"Grade III Astrocytoma, Grade IV Astrocytoma, Astrocytoma, Grade IV","enrollment":18},{"nctId":"NCT00584883","phase":"PHASE1","title":"A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2003-08","conditions":"Brain Tumor","enrollment":24},{"nctId":"NCT04541407","phase":"PHASE1","title":"Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2020-10-29","conditions":"Non Small Cell Lung Cancer, CNS Progression","enrollment":1},{"nctId":"NCT02573324","phase":"PHASE3","title":"A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-01-04","conditions":"Glioblastoma, Gliosarcoma","enrollment":691},{"nctId":"NCT05100641","phase":"PHASE3","title":"AV-GBM-1 vs Control as Adjunctive Therapy Following Surgery and RT/TMZ in Newly Diagnosed GBM","status":"NOT_YET_RECRUITING","sponsor":"Aivita Biomedical, Inc.","startDate":"2024-01","conditions":"Primary Glioblastoma","enrollment":672},{"nctId":"NCT01269424","phase":"PHASE1","title":"BG & TMZ Therapy of Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Stanton Gerson MD","startDate":"2011-11-22","conditions":"Glioblastoma Multiforme","enrollment":10},{"nctId":"NCT03867123","phase":"PHASE1","title":"A Study to Evaluate the Safety of LAM561 Added to Standard of Care in Newly-diagnosed Glioblastoma Patients","status":"COMPLETED","sponsor":"Laminar Pharmaceuticals","startDate":"2018-12-04","conditions":"Glioblastoma (GBM)","enrollment":18},{"nctId":"NCT00100802","phase":"PHASE2","title":"Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2005-03-21","conditions":"Anaplastic Astrocytoma, Central Nervous System Neoplasm, Glioblastoma","enrollment":118},{"nctId":"NCT01822275","phase":"PHASE2","title":"Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2013-05","conditions":"Histologically Proven Diagnosis of Glioblastoma or Gliosarcoma (WHO Grade IV)","enrollment":24},{"nctId":"NCT05512325","phase":"","title":"Study on Gene Evolution in Glioma Under Stress Therapy","status":"NOT_YET_RECRUITING","sponsor":"Henan Provincial People's Hospital","startDate":"2022-12-17","conditions":"Genetic Change","enrollment":100},{"nctId":"NCT04926168","phase":"","title":"6 Months Adjuvant Temozolomide (TMZ) vs No Adjuvant TMZ in Newly Diagnosed MGMT Methylated Glioblastoma (GBM)","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-03-01","conditions":"MGMT-Methylated Glioblastoma","enrollment":""},{"nctId":"NCT02358356","phase":"PHASE2","title":"Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study","status":"COMPLETED","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2015-11","conditions":"Midgut Neuroendocrine Tumours, Pancreatic Neuroendocrine Tumours","enrollment":75},{"nctId":"NCT01062399","phase":"PHASE1, PHASE2","title":"Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2010-12","conditions":"Brain and Central Nervous System Tumors","enrollment":279},{"nctId":"NCT03243461","phase":"PHASE3","title":"International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)","status":"UNKNOWN","sponsor":"University of Göttingen","startDate":"2018-07-17","conditions":"Glioblastoma WHO Grade IV, Diffuse Midline Glioma Histone 3 K27M WHO Grade IV, Anaplastic Astrocytoma WHO Grade III","enrollment":167},{"nctId":"NCT02871843","phase":"PHASE1","title":"RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas","status":"COMPLETED","sponsor":"EpicentRx, Inc.","startDate":"2017-02-14","conditions":"Glioblastoma, Oligodendroglioma, Anaplastic Oligodendroglioma","enrollment":19},{"nctId":"NCT04614493","phase":"PHASE2","title":"Innovative SonoCloud-9 Device for Blood Brain Barrier Opening in First Line Temozolomide Glioblastoma Patients.","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-09-11","conditions":"Initial Radiological Diagnosis Eligible for Tumor Resection, Initial Radiological Diagnosis Compatible With Newly Diagnosed Glioblastoma (IDH Wild-type), Eligible for the Standard of Care Including Concurrent Temoradiation and Adjuvant Temozolomide","enrollment":66},{"nctId":"NCT00805961","phase":"PHASE2","title":"RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2009-01","conditions":"Glioblastoma Multiforme","enrollment":68},{"nctId":"NCT01120639","phase":"PHASE1, PHASE2","title":"Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform","status":"COMPLETED","sponsor":"Stanford University","startDate":"2010-04","conditions":"Glioblastoma, Cancer of Brain and Nervous System, Glioblastoma Multiforme","enrollment":30},{"nctId":"NCT02046187","phase":"PHASE1, PHASE2","title":"Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma","status":"TERMINATED","sponsor":"St. Joseph's Hospital and Medical Center, Phoenix","startDate":"2013-10","conditions":"Glioblastoma (GBM)","enrollment":14},{"nctId":"NCT04902586","phase":"NA","title":"Effect of Radiotherapy Concurrent of TTFields in Patients With Glioblastoma","status":"UNKNOWN","sponsor":"Zhongnan Hospital","startDate":"2021-06-19","conditions":"Glioma, Glioblastoma","enrollment":30},{"nctId":"NCT04790097","phase":"NA","title":"FET-PET Directed Simultaneous In-field Boost for Primary GBM","status":"COMPLETED","sponsor":"Prof. Franciszek Lukaszczyk Memorial Oncology Center","startDate":"2017-02-21","conditions":"Glioblastoma Multiforme","enrollment":17},{"nctId":"NCT02903069","phase":"PHASE1","title":"Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer","status":"COMPLETED","sponsor":"Celgene","startDate":"2016-08-17","conditions":"Glioblastoma, Malignant Glioma","enrollment":66},{"nctId":"NCT02805179","phase":"PHASE2","title":"A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2016-09-22","conditions":"Glioma","enrollment":26},{"nctId":"NCT03980249","phase":"EARLY_PHASE1","title":"Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells","status":"WITHDRAWN","sponsor":"West Virginia University","startDate":"2020-09","conditions":"Glioblastoma, Glioblastoma Multiforme","enrollment":""},{"nctId":"NCT04829097","phase":"PHASE3","title":"Neoadjuvant Temozolomide Combined With Simultaneous IMRT for Treatment of Glioblastoma","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2020-11-01","conditions":"Glioblastoma","enrollment":80},{"nctId":"NCT04790955","phase":"","title":"Effect of Combination Therapy on SCLC After Initial Treatment Failure","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2021-03-01","conditions":"Small-cell Lung Cancer","enrollment":48},{"nctId":"NCT04725214","phase":"PHASE2","title":"Anlotinib Combined With STUPP for MGMT Nonmethylated Glioblastoma","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-01-15","conditions":"MGMT-Unmethylated Glioblastoma","enrollment":33},{"nctId":"NCT01507506","phase":"PHASE3","title":"Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma","status":"TERMINATED","sponsor":"Institut Claudius Regaud","startDate":"2011-03-15","conditions":"Glioblastoma","enrollment":180},{"nctId":"NCT00033280","phase":"PHASE2","title":"Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2002-07","conditions":"Brain and Central Nervous System Tumors","enrollment":42},{"nctId":"NCT03506139","phase":"PHASE2","title":"Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma","status":"WITHDRAWN","sponsor":"John M. Buatti","startDate":"2019-05-15","conditions":"Glioblastoma, Glioblastoma Multiforme","enrollment":""},{"nctId":"NCT01987830","phase":"NA","title":"Bevacizumab w / Temozolomide PET & Vascular MRI For GBM","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2013-11","conditions":"Recurrent Glioblastoma","enrollment":13},{"nctId":"NCT04536649","phase":"PHASE3","title":"Proton and Heavy Ion Beam Radiation vs. Photon Beam Radiation for Newly Diagnosed Glioblastoma.","status":"UNKNOWN","sponsor":"Shanghai Proton and Heavy Ion Center","startDate":"2020-10-01","conditions":"Glioblastoma","enrollment":369}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"concurrent temozolomide","genericName":"concurrent temozolomide","companyName":"Radiation Therapy Oncology Group","companyId":"radiation-therapy-oncology-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Temozolomide is an alkylating agent that works by interfering with DNA replication in cancer cells. Used for Glioblastoma multiforme, Anaplastic astrocytoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}